Adicet reports preclinical data for ADI-270, on track for IND filing in Q2 2024

Adicet Bio, Inc.

ADI-270 demonstrated robust anti-tumor activity in multiple CD70+ solid and hematological cancer models.
Preclinical data selected for oral presentation at ASGCT on May 10, 2024 in Baltimore.
ADI-270 uses CD27-based targeting and armored design to counteract tumor microenvironment and host T-cell clearance.
Company confirms IND submission for renal cell carcinoma remains on track for Q2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.